Jumo Health has launched PRISM, a clinical trial recruitment, enrolment, and retention system targeting persistent failures in research.
The system addresses challenges arising after enrolment, when medically eligible patients are not always fully prepared for participation.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This issue can lead to screen failure after consent, protocol deviations, site escalation, early dropout, and the need for costly rescue recruitment.
PRISM aims to operationalise readiness as a core execution variable. It reframes decision-making throughout recruitment and retention based on whether participation is likely to endure under real trial conditions.
The system models activation and readiness propensity, delivers decision-ready patients to sites through intelligent pre-screening and site handoff, applies decision science to reduce decision burden, implements early interventions to protect retention, and monitors readiness across the trial lifecycle.
PRISM is a patent-pending operating system offered to biopharma sponsors and research collaborators within specific therapeutic fields.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataJumo Health chairman Adam Cossman said: “From the beginning, Jumo Health has been the industry leader in readiness education, helping patients and their caregivers understand what clinical trial participation truly entails and make informed, confident decisions. PRISM is a natural extension of that mission.
“It takes the trust, health literacy, and expectation-setting programmes Jumo has built for hundreds of studies and operationalises it across recruitment, enrolment, and retention, so trials don’t just enrol patients but are designed for patients to succeed.”
Jumo Health CEO Brittany Erana said: “Clinical trials have spent decades optimising how patients are recruited, but very little time questioning whether those patients are truly prepared to participate and complete.
“PRISM defines a new execution model for clinical research, one that treats readiness as a first-class requirement, not an afterthought. When readiness is governed, trials become more predictable, more inclusive, and far more likely to finish as planned.”
